Literature DB >> 2469497

Characterization of two monoclonal antibodies against cytochrome b558 of human neutrophils.

A J Verhoeven1, B G Bolscher, L J Meerhof, R van Zwieten, J Keijer, R S Weening, D Roos.   

Abstract

Monoclonal antibodies (MoAbs) were raised against cytochrome b558, a membrane-bound component of the NADPH:O2 oxidoreductase in human neutrophils. This cytochrome consists of a low-molecular-weight (low-mol-wt) subunit of 22 to 23 Kd, probably encoded by an autosomal gene, and a high-mol-wt subunit of 75 to 90 Kd, encoded on the X-chromosome. MoAb 449 reacts with the low-mol-wt subunit and MoAb 48 with the high-mol-wt subunit on Western blots of purified cytochrome b558 and on blots of whole neutrophil extracts. In extracts of neutrophils from patients with chronic granulomatous disease (CGD) in which cytochrome b558 is not detectable by spectrophotometric methods, the low-mol-wt subunit is present, albeit in a much smaller amount. The high-mol-wt subunit is not detected by MoAb 48 in neutrophils of patients with X-linked CGD and in neutrophils of patients with the autosomal, cytochrome-b558-negative form of the disease. These results can be explained by a marked instability of these subunits when the synthesis of either of the two is disturbed. In differentiated HL-60 cells, the high-mol-wt subunit appears to be present in a different form. Cloning of the low-mol-wt subunit with the help of MoAb 449 suggests the presence of a heme-binding site on this subunit. By comparison of the binding characteristics of MoAb 449 to intact and permeabilized neutrophils with those of MoAb 7D5, recently isolated by Nakamura et al (Blood 69:1404, 1987), the low-mol-wt subunit was established as a transmembrane protein.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2469497

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  Cooperation of p40(phox) with p47(phox) for Nox2-based NADPH oxidase activation during Fcγ receptor (FcγR)-mediated phagocytosis: mechanism for acquisition of p40(phox) phosphatidylinositol 3-phosphate (PI(3)P) binding.

Authors:  Takehiko Ueyama; Junya Nakakita; Takashi Nakamura; Takeshi Kobayashi; Toshihiro Kobayashi; Jeonghyun Son; Megumi Sakuma; Hirofumi Sakaguchi; Thomas L Leto; Naoaki Saito
Journal:  J Biol Chem       Date:  2011-09-28       Impact factor: 5.157

2.  Involvement of Rac1 in activation of multicomponent Nox1- and Nox3-based NADPH oxidases.

Authors:  Takehiko Ueyama; Miklós Geiszt; Thomas L Leto
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

3.  A novel polymorphism in the coding region of CYBB, the human gp91-phox gene.

Authors:  F Kuribayashi; M de Boer; J H Leusen; A J Verhoeven; D Roos
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

4.  Treatment of patients with chronic granulomatous disease with recombinant human interferon-gamma does not improve neutrophil oxidative metabolism, cytochrome b558 content or levels of four anti-microbial proteins.

Authors:  T J Mühlebach; J Gabay; C F Nathan; C Erny; G Dopfer; H Schroten; V Wahn; R A Seger
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

5.  Guidelines for the Detection of NADPH Oxidases by Immunoblot and RT-qPCR.

Authors:  Becky A Diebold; S Garrett Wilder; Xavier De Deken; Jennifer L Meitzler; James H Doroshow; James W McCoy; Yerun Zhu; J David Lambeth
Journal:  Methods Mol Biol       Date:  2019

6.  Homocysteine-induced cardiomyocyte apoptosis and plasma membrane flip-flop are independent of S-adenosylhomocysteine: a crucial role for nuclear p47(phox).

Authors:  Jessica A Sipkens; Paul A J Krijnen; Nynke E Hahn; Melissa Wassink; Christof Meischl; Desirée E C Smith; René J P Musters; Coen D A Stehouwer; Jan A Rauwerda; Victor W M van Hinsbergh; Hans W M Niessen
Journal:  Mol Cell Biochem       Date:  2011-07-08       Impact factor: 3.396

7.  A point mutation in gp91-phox of cytochrome b558 of the human NADPH oxidase leading to defective translocation of the cytosolic proteins p47-phox and p67-phox.

Authors:  J H Leusen; M de Boer; B G Bolscher; P M Hilarius; R S Weening; H D Ochs; D Roos; A J Verhoeven
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

8.  Functional analysis of two-amino acid substitutions in gp91 phox in a patient with X-linked flavocytochrome b558-positive chronic granulomatous disease by means of transgenic PLB-985 cells.

Authors:  Clara Bionda; Xing Jun Li; Robin van Bruggen; Michel Eppink; Dirk Roos; Françoise Morel; Marie-José Stasia
Journal:  Hum Genet       Date:  2004-08-24       Impact factor: 4.132

9.  Identification of allele-specific p22-phox mutations in a compound heterozygous patient with chronic granulomatous disease by mismatch PCR and restriction enzyme analysis.

Authors:  J P Hossle; M de Boer; R A Seger; D Roos
Journal:  Hum Genet       Date:  1994-04       Impact factor: 4.132

10.  Gene targeting of X chromosome-linked chronic granulomatous disease locus in a human myeloid leukemia cell line and rescue by expression of recombinant gp91phox.

Authors:  L Zhen; A A King; Y Xiao; S J Chanock; S H Orkin; M C Dinauer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.